Autopsy report · NCT00841035

7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients

“Sponsor stopped due to slow enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 5 months before it stopped.
• 6 participants enrolled.
• Results were posted on the registry 3 years 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University of Alabama at Birmingham

Sponsor type

University, hospital or other

Conditions

Pancreatic Cancer

Interventions

erlotinib

Participants

6

Sites

1

Countries

United States

Trials that died the same way

• Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab
  “Slow enrollment and change in sponsor direction” (85% match in meaning)
• Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma
  “Study stopped due to slow enrollment” (79% match in meaning)
• A Clinical Investigation Evaluating Peristeen® Performance
  “Lack of enrollment - Sponsor decision” (79% match in meaning)
• RCT: Fentanyl Plus Ketamine Versus Fentanyl Alone for Acute Burn Pain
  “Funding withdrawn - slow enrollment” (78% match in meaning)
• A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
  “Due to low enrollment, the Sponsor decided to prematurely terminate the study” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.